PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 1, 1994Current Opinion in Neurology

Neuroleptic malignant syndrome

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with Neuroleptic malignant syndrome (NMS) or Parkinson's disease withdrawn from medication

Design

Review

Key result

Neuroleptic malignant syndrome is a life-threatening complication characterized by functional dopamine deficiency, managed primarily by discontinuing causative drugs and providing supportive care.

Authors

JKJohannes KornhuberMWMichael Weller

Discussion

Loading...

Member takes

Overview

NMS is a life-threatening condition primarily caused by functional dopamine deficiency, requiring prompt recognition and discontinuation of triggering agents for a good outcome.

Structured PICO

P
Population
Patients with Neuroleptic malignant syndrome (NMS) or Parkinson's disease withdrawn from medication
I
Intervention
Management of NMS including discontinuation of causative drugs, readjustment of parkinsonian therapy, supportive care, and controversial measures like dopamine receptor agonists, excitatory amino acid antagonists, or dantrolene

NMS is a life-threatening condition primarily caused by functional dopamine deficiency, requiring prompt recognition and discontinuation of triggering agents for a good outcome.

Cite This Study

Kornhuber et al. (1994) conducted a review in Neuroleptic malignant syndrome. Neuroleptic malignant syndrome is a life-threatening complication characterized by functional dopamine deficiency, managed primarily by discontinuing causative drugs and providing supportive care.

synapsesocial.com/papers/6aa4773d4093a38aba2bc449https://doi.org/10.1097/00019052-199408000-00013
View Full Paper
Ask AI
Bookmark
Share